Abstract
Background. The immune deficiency of human immunodeficiency virus (HIV) infection is not fully corrected with ARV therapy. Interleukin-7 (IL-7) can boost CD4 T-cell counts, but optimal dosing and mechanisms of cellular increases need to be defined. Methods. We performed a randomized placebo-controlled dose escalation (10, 20 and 30 g/kg) trial of 3 weekly doses of recombinant human IL-7 (rhIL-7) in ARV-treated HIV-infected persons with CD4 T-cell counts between 101 and 400 cells/L and plasma HIV levels
Original language | English |
---|---|
Pages (from-to) | 291-300 |
Number of pages | 10 |
Journal | Clinical Infectious Diseases |
Volume | 55 |
Issue number | 2 |
DOIs | |
Publication status | Published - Jul 15 2012 |
ASJC Scopus subject areas
- Infectious Diseases
- Microbiology (medical)